FIELD: biotechnology.
SUBSTANCE: presented inventions: an anti-TRBC1 antigen-binding domain that is characterized by variable chain sequences, a chimeric antigen receptor (CAR) capable of binding the TRBC1, an antibody capable of binding the TRBC1 that contains an anti-TRBC1 antigen-binding domain, a bispecific T-cell engager (BiTE) that is capable of recognizing the TRBC1 and activate the T cell, and the antibody-drug conjugate. Also provided are: a nucleic acid molecule that encodes CAR, a vector for providing CAR expression, a cytolytic cell and a method for its production, a method for treating TRBC1-expressing T-cell lymphoma or leukaemia in a subject, a pharmaceutical composition for eliminating cells that express TRBC1, and its use in the manufacture of medicinal products.
EFFECT: invention allows to use it in cancer therapy, in particular - for the treatment of TRBC1-expressing T-cell lymphoma or leukaemia in a subject.
16 cl, 14 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CELL | 2015 |
|
RU2768019C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
